PMID- 19699755
OWN - NLM
STAT- MEDLINE
DCOM- 20100413
LR  - 20211020
IS  - 1873-7064 (Electronic)
IS  - 0028-3908 (Print)
IS  - 0028-3908 (Linking)
VI  - 58
IP  - 2
DP  - 2010 Feb
TI  - Attenuation of morphine antinociceptive tolerance by a CB(1) receptor agonist and 
      an NMDA receptor antagonist: Interactive effects.
PG  - 544-50
LID - 10.1016/j.neuropharm.2009.08.005 [doi]
AB  - CB(1) cannabinoid (CB(1)) receptor agonists and N-Methyl-d-Aspartate (NMDA) 
      receptor antagonists attenuate the development of morphine antinociceptive 
      tolerance. The present study used dose-addition analysis to evaluate CB(1)/NMDA 
      receptor interactions on this endpoint. Chronic morphine administration (5 days, 
      100 mg/kg, twice daily) resulted in a 2.8-fold rightward shift in the morphine 
      dose-effect curve. Co-administration of either the CB(1) receptor agonist 
      CP-55940 
      (5-(1,1-Dimethylheptyl)-2-[5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]phenol; 
      0.32-1.0 mg/kg) or the NMDA receptor antagonist 
      (-)-6-phosphonomethyl-deca-hydroisoquinoline-3-carboxylic acid (LY235959; 1.0-3.2 
      mg/kg) with morphine dose-dependently attenuated morphine tolerance. The relative 
      potency of each drug alone was quantified using a defined level of effect 
      (one-quarter log shift in the morphine dose-effect curve), resulting in 
      equieffective doses of 0.42 mg/kg and 1.1 mg/kg for CP-55940 and LY235959, 
      respectively. Subsequent experiments assessed CP-55940/LY235959 interactions 
      using a fixed-proportion design. Co-administration of CP-55940/LY235959 mixtures 
      (1:1, 1:3.2, or 1:10 CP-55940/LY235959) with morphine dose-dependently attenuated 
      morphine tolerance. Isobolographic and dose-addition analysis were used to 
      statistically compare the experimentally determined potency for each mixture 
      (z(mix)) with predicted additive potency (z(add)). Mixtures of 1:1 and 1:3.2 
      CP-55940/LY235959 produced additive effects (z(add) = z(mix)), while the mixture 
      of 1:10 CP-55940/LY235959 produced a supra-additive effect (z(add) > z(mix)). 
      These results suggest that CP-55940 and LY235959 produce additive or 
      supra-additive attenuation of morphine antinociceptive tolerance after repeated 
      morphine administration, depending on their relative concentrations.
CI  - 2009 Elsevier Ltd. All rights reserved.
FAU - Fischer, Bradford D
AU  - Fischer BD
AD  - Department of Psychology, University of North Carolina at Chapel Hill, Chapel 
      Hill, NC 27599, USA. bradford_fischer@hms.harvard.edu
FAU - Ward, Sara J
AU  - Ward SJ
FAU - Henry, Fredrick E
AU  - Henry FE
FAU - Dykstra, Linda A
AU  - Dykstra LA
LA  - eng
GR  - T32-DA07244/DA/NIDA NIH HHS/United States
GR  - R01 DA002749-32/DA/NIDA NIH HHS/United States
GR  - T32 DA007244/DA/NIDA NIH HHS/United States
GR  - F31 DA022788/DA/NIDA NIH HHS/United States
GR  - R01 DA002749/DA/NIDA NIH HHS/United States
GR  - T32 DA007244-20/DA/NIDA NIH HHS/United States
GR  - F31 DA022788-01A1/DA/NIDA NIH HHS/United States
GR  - R01-DA02749/DA/NIDA NIH HHS/United States
GR  - F31-DA022788/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20090821
PL  - England
TA  - Neuropharmacology
JT  - Neuropharmacology
JID - 0236217
RN  - 0 (Analgesics)
RN  - 0 (Analgesics, Opioid)
RN  - 0 (Cyclohexanols)
RN  - 0 (Excitatory Amino Acid Antagonists)
RN  - 0 (Isoquinolines)
RN  - 0 (Receptor, Cannabinoid, CB1)
RN  - 0 (Receptors, N-Methyl-D-Aspartate)
RN  - 76I7G6D29C (Morphine)
RN  - 83003-12-7 
      (3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol)
RN  - AR2BHC0C6P (LY 235959)
SB  - IM
MH  - Analgesics/administration & dosage/pharmacology
MH  - Analgesics, Opioid/administration & dosage/*pharmacology
MH  - Animals
MH  - Cyclohexanols/administration & dosage/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - *Drug Tolerance
MH  - Excitatory Amino Acid Antagonists/administration & dosage/pharmacology
MH  - Hot Temperature
MH  - Isoquinolines/administration & dosage/pharmacology
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Morphine/administration & dosage/*pharmacology
MH  - Pain/*drug therapy/metabolism
MH  - Pain Measurement
MH  - Receptor, Cannabinoid, CB1/*agonists/metabolism
MH  - Receptors, N-Methyl-D-Aspartate/*antagonists & inhibitors/metabolism
PMC - PMC2813317
MID - NIHMS140752
EDAT- 2009/08/25 09:00
MHDA- 2010/04/14 06:00
PMCR- 2011/02/01
CRDT- 2009/08/25 09:00
PHST- 2009/07/24 00:00 [received]
PHST- 2009/08/14 00:00 [revised]
PHST- 2009/08/16 00:00 [accepted]
PHST- 2009/08/25 09:00 [entrez]
PHST- 2009/08/25 09:00 [pubmed]
PHST- 2010/04/14 06:00 [medline]
PHST- 2011/02/01 00:00 [pmc-release]
AID - S0028-3908(09)00275-5 [pii]
AID - 10.1016/j.neuropharm.2009.08.005 [doi]
PST - ppublish
SO  - Neuropharmacology. 2010 Feb;58(2):544-50. doi: 10.1016/j.neuropharm.2009.08.005. 
      Epub 2009 Aug 21.